HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib.

Abstract
We report the case of a young, never-smoker woman with Li-Fraumeni syndrome and advanced lung adenocarcinoma refractory to multiple lines of conventional chemotherapy and negative for actionable alterations by routine testing. Comprehensive genomic profiling by clinical-grade next generation sequencing was performed on 3320 exons of 184 cancer-related genes and 37 introns of 14 genes frequently rearranged in cancer. The tumor was found to harbor both EGFR L858R and ERBB2 S310F alterations and also tested positive for a known TP53 germline mutation. The presence of the EGFR mutation was further validated by direct sequencing. Based on these results, a dual EGFR/ERBB2 inhibitor, afatinib, was chosen for treatment. The patient achieved a rapid, complete, and durable response to afatinib monotherapy, both clinically and radiographically. The treatment was very well tolerated. This unique case raises practical questions as to the challenges of molecular testing and highlights the potential association of p53 mutations with concurrent EGFR and ERBB2 aberrations. As this case powerfully illustrates, the combination of broad genomic profiling and targeted therapy guided by mutational analysis offers the possibility of precision management of refractory advanced adenocarcinoma in the background of neoplastic syndromes.
AuthorsYuxia Jia, Siraj M Ali, Shumaila Saad, Courtney A Chan, Vincent A Miller, Balazs Halmos
JournalCancer biology & therapy (Cancer Biol Ther) Vol. 15 Issue 8 Pg. 970-4 (Aug 2014) ISSN: 1555-8576 [Electronic] United States
PMID24835218 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Quinazolines
  • Afatinib
  • ERBB2 protein, human
  • ErbB Receptors
  • Receptor, ErbB-2
Topics
  • Adenocarcinoma (complications, drug therapy, genetics, pathology)
  • Adenocarcinoma of Lung
  • Afatinib
  • Antineoplastic Agents (therapeutic use)
  • ErbB Receptors (genetics)
  • Female
  • Humans
  • Li-Fraumeni Syndrome (complications, drug therapy)
  • Lung Neoplasms (complications, drug therapy, genetics, pathology)
  • Middle Aged
  • Mutation
  • Neoplasm Metastasis
  • Protein Kinase Inhibitors (therapeutic use)
  • Protein Structure, Tertiary
  • Quinazolines (therapeutic use)
  • Receptor, ErbB-2 (antagonists & inhibitors, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: